MIR497 (MicroRNA 497)

[This retracts the article DOI: 10.3389/fgene.2019.01385.].

The study demonstrated that miR-497/SK-loaded nanobubbles simultaneously boosts ICD and blocks the PD-1/PD-L1 pathway in immunotherapy. This finding offers a theoretical foundation for the effective eradication of tumor cells and the development of a highly efficient synergistic treatment strategy for HCC.

Preoperative ALB, Hb, miR-497-5p, KLK5, Ang-2 levels and ALB-Hb scores were notable prognostic factors for patients with stage II-III CRC following radical resection, demonstrating high predictive value for poor postoperative outcomes. The present study provided clinically relevant indicators to screen high-risk patients with potential poor prognosis following radical surgery for stages II-III CRC.

FAM171A2 demonstrates context-dependent expressions that are modulated post-transcriptionally in gynecologic cancers. While it is not independently prognostic, it may serve as a molecular hub at the intersection of neuronal and immune pathways, warranting further mechanistic investigations and exploration as a panel-based biomarker.

MiR-126-5p, miR-150-5p, miR-214-3p, and miR-452-5p all showed a decrease in expression at at least one timepoint following splenectomy. These miRNAs have been previously shown to have roles in angiogenesis and pathways known to be involved in the pathogenesis of hemangiosarcoma and may be prospective targets for a minimally invasive diagnostic panel for the presence of splenic hemangiosarcoma.

If a mass is not hemangiosarcoma, owners may be more likely to proceed with surgery rather than euthanasia. Knowing that a mass is hemangiosarcoma will provide information to owners on the need for adjuvant therapy following surgery.

Molecular interaction analysis indicate that SOX9-AS1 functions as a molecular sponge for miR-497-5p, thereby increasing E2F3 expression. Our work unveiled a novel mechanism by which SOX9-AS1 promotes EC development, suggesting that targeting the SOX9-AS1/miR-497-5p/E2F3 axis may represent a potential therapeutic strategy for EC.

The LINC01214/miR-497-3p/HSP90AB1 axis regulated NSCLC cell proliferation, migration, and invasion. LINC01214, a potential biomarker, contributed to the progression of NSCLC through the miR-497-3p/HSP90AB1 axis by promoting cell proliferation and motility.

This four-phase study suggests that exosomal miRNA panels have potential diagnostic value for early-stage lung cancer. The UDR platform enabled the selection of a four-miRNA panel (miR-150-5p, miR-301b-3p, miR-369-3p, and miR-497-5p), with bioinformatics analyses providing supportive evidence.

The retraction has been agreed to because of evidence that significant portions of multiple figures were duplicated, affecting the interpretation of the data and results presented. The authors agree with the retraction.

Furthermore, our data indicate that miR-497-5p is upregulated in response to Brusatol treatment, which subsequently binds to the 3'UTR of NUCKS1 and downregulates its expression in HNSCC. Collectively, these findings highlight the critical role and regulatory mechanisms of NUCKS1 in HNSCC, suggesting that NUCKS1 antagonizes the antitumor effects of Brusatol and exacerbates the malignancy of HNSCC cells via transcriptional upregulation of S100A9.